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9 Abstract Cyclin-dependent kinases CDK4 and CDK6 are
10 essential for the control of the cell cycle through the G1
11 phase. Aberrant expression of CDK4 and CDK6 is a hall-
12 mark of cancer, which would suggest that CDK4 and CDK6
13 are attractive targets for cancer therapy. Herein, we report
14 that calcein AM is a potent specific inhibitor of CDK4 and
15 CDK6 in HCT116 human colon adenocarcinoma cells,
16 inhibiting retinoblastoma protein (pRb) phosphorylation and
17 inducing cell cycle arrest in the G1 phase. The metabolic
18 effects of calcein AM (the calcein acetoxymethyl-ester) on
19HCT116 cells were also evaluated and the flux between the
20oxidative and non-oxidative branches of the pentose phos-
21phate pathway was significantly altered. To elucidate whe-
22ther these metabolic changes were due to the inhibition of
23CDK4 and CDK6, we also characterized the metabolic
24profile of a CDK4, CDK6 and CDK2 triple knockout of
25mouse embryonic fibroblasts. The results show that the
26metabolic profile associated with the depletion of CDK4,
27CDK6 and CDK2 coincides with the metabolic changes
28induced by calcein AM on HCT116 cells, thus confirming
29that the inhibition of CDK4 and CDK6 disrupts the balance
30between the oxidative and non-oxidative branches of the
31pentose phosphate pathway. Taken together, these results
32indicate that low doses of calcein can halt cell division and
33kill tumor cells. Thus, selective inhibition of CDK4 and
34CDK6 may be of greater pharmacological interest, since
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35 inhibitors of these kinases affect both cell cycle progression
36 and the robust metabolic profile of tumors.
37
38 Keywords Cyclin dependent kinases  CDK-inhibitor 
39 Tracer-based metabolomics  Pentose phosphate pathway 
40 Phase plane analysis
41 Abbreviations
42 Calcein AM Calcein acetoxymethyl-ester
43 CDK Cyclin dependent kinase
44 DMEM Dulbecco’s modified eagle medium
45 FCS Fetal calf serum
46 Ct MEF Mouse embryonic fibroblast
47 PBS Phosphate buffer saline
48 PPP Pentose phosphate pathway
49 pRb Retinoblastoma protein
50 TKO MEF Mouse embryonic fibroblast knockout
for CDK4, CDK6 and CDK2
51
52
53 1 Introduction
54 Typical proliferation of eukaryotic cells involves an orderly
55 progression through four distinct phases of the cell cycle: G1,
56 S, G2, and M (Malumbres and Barbacid 2001; Sherr 1996).
57 The first step of the G1/S transition of the cell cycle is reg-
58 ulated by cyclin-dependent kinases (CDKs: EC 2.7.11.22),
59 CDK4 and CDK6 and their inhibitors, p16
INK4a and
60 p15
INK4b. According to the long-prevailing model of cell
61 cycle control in mammalian cells, cyclin D-CDK4, cyclin
62 D-CDK6 and cyclin E-CDK2 complexes are sequentially
63 required to promote cell cycle entrance from quiescence,
64 progression through the G1 phase and transition from the G1
65 to the S-phase in response to mitogenic stimulation. Cell
66 culture and biochemical studies have indicated that cyclin
67 D-CDK4, cyclin D-CDK6 and cyclin E-CDK2 complexes
68 are essential and rate-limiting for the phosphorylation and
69 inactivation of the tumor suppressor retinoblastoma protein
70 (pRb) and the subsequent induction of the E2F-dependent
71 transcriptional program required to enter the S-phase
72 (Lundberg andWeinberg 1998;Malumbres et al. 2004; Sherr
73 and Roberts 2004). This step of the cell cycle is critical. If the
74 cell passes through the restriction point (R), it becomes
75 insensitive to extracellular stimuli and is committed to
76 entering the S-phase. Since almost all the regulators of this
77 cell cycle phase are mutated in cancer (Graf et al. 2009), this
78 phase has been considered as a valid therapeutic target. Since
79 most mutations in human cancers affect CDK4 and CDK6 or
80 their regulators (Hall and Peters 1996), and preclinical data
81 indicate that the inhibition of cyclin D-dependent kinase
82 activity may have therapeutic benefits (Graf et al. 2009;
83Malumbres and Barbacid 2006; Shapiro 2006; Yu et al.
842006), interest in CDK4 and CDK6 as promising targets for
85inhibiting cell cycle progression has been generated.
86Another important and critical feature of tumor cells is
87their metabolic adaptation, which provides them with
88metabolites and energy to progress through the cell cycle.
89This adaptation includes the phenomenon known as the
90‘‘Warburg effect’’ (high glycolysis in the presence of oxy-
91gen) (Warburg 1956), a high glutamine uptake, the activation
92of biosynthetic pathways and the over-expression of some
93glycolytic isoenzymes (Viza´n et al. 2008). In recent years, it
94has become accepted that the metabolic adaptation of tumor
95cells also involves an enhancement of pentose phosphate
96pathway (PPP) fluxes and a specific imbalance between its
97two branches in favor of the oxidative branch versus the non-
98oxidative branch to maintain the high proliferative rates
99(Kuo et al. 2000; Poulsen and Frederiksen 1981; Ramos-
100Montoya et al. 2006). In previous studies, we have demon-
101strated that this balance between the oxidative and non-
102oxidative branches of the PPP is necessary to maintain the
103metabolic efficiency of the cancer cell for growth and pro-
104liferation, and that it can be a weakness in the robust tumor
105metabolic adaptation (Ramos-Montoya et al. 2006). PPP is
106also specifically regulated during cell cycle progression in
107tumor cells (Vizan et al. 2009).
108In the present study, we identified calcein (4050-bis(N,N-
109bis(carboxymethyl) aminomethyl) fluorescein) as a putative
110inhibitor of CDK4 and CDK6 that mimics the natural
111inhibitor p16
INK4a in HCT116 cells, through the use of new
112bioinformatic tools (Villacanas et al. 2002; Villacanas and
113Rubio-Martinez 2006), docking procedures (Rubio-Marti-
114nez et al. 2005) and molecular assays. Moreover, we provide
115experimental evidence that this CDK4 and CDK6 inhibitor
116counteracts metabolic adaptations which are characteristic
117of tumor cells, and that this metabolic fingerprint coincides
118with that obtained from a mouse embryonic fibroblast
119knockout for CDK4, CDK6 and CDK2 cell line. We dem-
120onstrate not only that calcein is a promising agent that could
121be a key factor in the development of a new family of
122selective cyclin D-dependent kinase inhibitors, but also that
123inhibition of CDK4 and CDK6 impairs metabolic adapta-
124tions that support tumor cell cycle progression.
1252 Materials and methods
1262.1 Materials
127Dulbecco’s modified Eagle Medium (DMEM), F-12 HAM
128Nutrient mixture with L-glutamine, MEM-EAGLE non-
129essential aminoacid solution 9100, antibiotic (100 U/ml
130penicillin, 100 mg/ml streptomycin), Dulbecco’s Phosphate
131buffer saline (PBS), Trypsin EDTA solution C (0.05%
M. Zanuy et al.
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132 trypsin–0.02% EDTA), L-glutamine solution 200 mM and
133 sodium pyruvate solution 100 mM were obtained from
134 Biological Industries; Fetal calf serum (FCS) and Trizol
135 were from Invitrogen; SDSwas from Fluka; Coomassie blue
136 was from Biorad; HEPES andMgCl2were fromApplichem;
137 A-Sepharose was from Pierce; the [c-32P]ATP, 3000
138 Ci/mmol, 10 mCi/ml and ECL were from Amersham; his-
139 tone H1 was from Boehringer Mannheim; Bradford reagent
140 (500-0006), Acrylamide (161-0158) and peroxidase-cou-
141 pled secondary antibody were from Bio-Rad Laboratories;
142 anti-CDK6 (sc-177), anti-CDK4 (sc-260-R), anti-cyclin
143 D3 (sc-182) and anti-p16INK4a (sc-468) were from Santa
144 Cruz Biotechnology; anti-cyclin D1 (06-137), anti-CDK2
145 (06-505) and anti-cyclin B1 (05-158) were from Upstate
146 Biotechnology; anti-actin (691001) was from MP Biomed-
147 icals; anti-phospho-Rb (Ser780) was from Cell Signaling
148 Technology; pGST-Rb (379-928) (gift of Dr Wang, San
149 Diego, CA, USA) fusion protein was expressed and purified
150 following Smith and Johnson (1988) and Frangioni and Neel
151 (1993). All other reagents were from Sigma Chemical CO.
152 2.2 Molecular modeling
153 Construction and molecular dynamics simulations of the
154 CDK6-p16
INK4a complex and the determination of their
155 interactions were carried out as described Villacan˜as et al.
156 2002. All hot spots of the CDK6-p16
INK4a interaction
157 surface were monitored throughout the production time to
158 obtain its pharmacophores. Catalyst (Accelrys, Inc., San
159 Diego, CA, USA) software was then used to obtain com-
160 pounds that matched the different interaction pharmaco-
161 phores. Selected compounds were docked into CDK6 with
162 an in-house program (Rubio-Martinez 2005) and, finally, a
163 visual structure analysis was carried out to reduce the
164 number of final modeled complexes. More details can be
165 found in supplementary material.
166 2.3 Cell culture
167 Human colon carcinoma HCT116 cells (donated by Dr.
168 Capella`, the Institut Catala` d’Oncologia, Barcelona, Spain)
169 were grown in DMEM:HAM’s F12 (1:1), supplemented
170 with 10% heat-inactivated FCS, 2 mM glutamine, 1 mM
171 sodium pyruvate, 1% non-essential amino acids, 50 mU/ml
172 penicillin and 50 lg/ml streptomycin. All cell cultures
173 were carried out at 37C in a humidified atmosphere with
174 5% CO2.
175 Mouse embryonic fibroblast (Ct MEF) and mouse
176 embryonic fibroblast knockout for CDK4, CDK6 and
177 CDK2 (TKO MEF) cell lines, obtained from Dr. Barbacid
178 (Centro Nacional de Investigaciones Oncolo´gicas, Madrid,
179 Spain) (Santamaria and Ortega 2006), were grown as a
180 monolayer culture in minimum essential medium (DMEM
181with L-glutamine, without glucose or sodium pyruvate) in
182the presence of 10% heat-inactivated FCS, 10 mM D-glu-
183cose and 0.1% streptomycin/penicillin in standard culture
184conditions. They were incubated at 37C, 80% humidity,
1855% CO2, and 3% O2. Two different clones of each were
186used in order to discard the effect of immortalization: Ct
187MEF: LD179.10.1 and LD207.3.1 and TKO MEF:
188LD1043.7.1 and LD1043.6.1.
1892.4 Immunoprecipitation and kinase assays
190For the kinase assays, immunoprecipitationswere performed
191as described by Harlow and Lane (Harlow and Lane 1988).
192HCT116 cells were lysed for 30 min at 4C in IP buffer
193(50 mM HEPES pH 7.5, 150 mM NaCl, 2.5 mM EGTA,
1941 mM EDTA, 0.1% Tween 20, 10% glycerol, 1 mM DTT,
1951 mM phenyl methyl sulfonyl fluoride, 1 lg/ml aprotinin,
19610 lg/ml leupeptin, 10 mM ß-glycerophosphate, 0.1 mM
197Na3VO4 and 1 mM NaF). Lysates were sonicated twice for
19810 s at 4C and clarified by centrifugation at 10,0009g for
19910 min. The supernatant fraction protein content was mea-
200sured using the Bradford method (Bradford 1976), and
201400 lg of protein from the lysates were incubated with 4 lg
202of antibody (CDK6, CDK4, cyclin-D1, cyclin-D3, cyclin-B1
203or CDK2) or with 1 ll of normal rabbit serum or normal
204mouse serum (controls) O/N shaking at 4C. Protein
205immunocomplexes were then incubated with 20 ll protein
206A-Sepharose for 1 h at 4C, collected by centrifugation and
207washed four times in IP buffer and twice in kinase buffer
208(50 mM HEPES pH 7.4, 10 mM MgCl2, 2.5 mM EGTA,
2090.1 mM Na3VO4, 10 mM ß-glycerophosphate and 1 mM
210DTT). They were then incubated in kinase buffer containing
2112 Ci [c-32P]ATP and 1 lg pGST-Rb (379-928) fusion pro-
212tein for CDK6 and CDK4 kinase assays, or 3 lg histone H1
213for CDK1 and CDK2 kinase assays, for 30 min. at 30C in a
214final volume of 30 ll. The samples were pooled and redis-
215tributed to assure equal amounts of all the reagents and
216immunoprecipitated CDK. Finally, the samples were boiled
217for 5 min and electrophoresed on SDS-polyacrylamide gels,
218essentially as described by Laemmli (1970), and the gels
219were stained with coomassie brilliant blue, dried, and
220exposed to X-ray films at -80C. The intensity of radioac-
221tivity was measured with Typhoon Trio and Trio 9200 (GE
222Healthcare). p21
Kip/Cip and purified p16INK4a were used as a
223positive control of inhibition.
2242.5 Gel electrophoresis and immunoblotting
225Cells were lysed in a buffer containing 2% SDS, 67 mM
226Tris–HCl pH 6.8 and 10 mM EDTA and sonicated twice
227for 10 s (4C). Protein content was measured according to
228the Lowry procedure, using bovine serum albumin (BSA)
229as standard. The extracts were electrophoresed in SDS-
CDK inhibition perturbs pentose phosphate pathway and cell viability
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230 polyacrylamide gels, essentially as described by Comin-
231 Anduix et al. 2002 and Laemmli 1970. After electropho-
232 resis, the proteins were transferred to Immobilon-P strips
233 for 1.5 h at 70 V. The sheets were preincubated in TBS
234 (20 mM Tris–HCl pH 7.5, 150 mM NaCl), 0.05% Tween
235 20 and 3% BSA for 1 h at room temperature and then
236 incubated for 1 h at room temperature in TBS, 0.05%
237 Tween 20, 3% BSA containing anti-phospho-Rb (Ser780),
238 anti-CDK4 (sc-260), anti-CDK2 (06-505) or anti-actin
239 (60100) antibodies. After washing in TBS, 0.05% Tween
240 20 (three times, 10 min each), the sheets were incubated
241 with a peroxidase-coupled secondary antibody (1:3000
242 dilution) for 1 h at room temperature. After incubation, the
243 sheets were washed twice in TBS, 0.05% Tween 20 and
244 once in TBS. The reaction was visualized using ECL. The
245 Image LAS-3000 Photo Version 2.0 (Fujifilm) was used to
246 analyze the chemiluminescence.
247 2.6 Viability assay
248 The assay was performed using a variation of the method
249 described by Mosmann (Matito et al. 2003; Mosmann
250 1983; Ramos-Montoya et al. 2006). Growing concentra-
251 tions of the product were plated in 96-well flat-bottomed
252 microtiter plates to a final volume of 200 ll where
253 1700 cells/well had been seeded 24 h before. After incu-
254 bation for 72 h, MTT at a final concentration of 0.5 mg/ml
255 was added. After 1 h of incubation, the generated formazan
256 was dissolved with 100 ll of DMSO per well. The absor-
257 bance was measured on an ELISA plate reader (Merck
258 ELISA System MIOS version 3.2., Tecan Sunrise, Tecan
259 Group Ltd.) at 550 nm. The concentrations that caused
260 50% inhibition of cell viability (IC50) were calculated.
261 2.7 Cell culture synchronization and cell cycle analysis
262 HCT116 cells were brought to 95% cell confluence and
263 kept confluent for 24 h with medium containing 0.5% FCS.
264 Cells were then seeded to 50–60% cell confluence in a
265 medium with 10% heat-inactivated FCS. Calcein AM
266 2 lM was added.
267 In order to determine the proportion of cells in each cell
268 cycle phase (G1, S or G2), cell cycle analysis was assessed
269 with flow cytometry using a fluorescence-activated cell
270 sorter (FACS). Approximately 500,000 cells were resus-
271 pended in 0.5 ml PBS followed by the addition of 4.5 ml
272 70% (v/v) ethanol (Matito et al. 2003). Cells were briefly
273 stained in PBS containing 50 lg/ml propidium iodide,
274 10 lg/ml DNAse free RNAse and 0.1% Triton
 X-100.
275 FACS analysis was carried out at 488 nm in an Epics XL
276 flow cytometer (Beckman Coulter). Data from 12,000 cells
277 were collected and analyzed using the MultiCycle program
278 (Phoenix Flow Systems).
2792.8 Isotopologue distribution analysis
280Tracer studies were carried out by incubating the cells in the
281presence of the corresponding incubation medium con-
282taining 10 mM glucose enriched by 50% in the tracer
283[1,2-
13C2]-D-glucose. After incubation for 72 h, the cell
284medium was removed, thereby separating the incubation
285medium from the cells adhered to the dishes, and all frac-
286tions were frozen in liquid nitrogen and stored at -80C
287until processing.
288Mass spectral data were obtained on an HP5973 mass
289selective detector connected to an HP6890 gas chromato-
290graph (HCT116 with calcein AM assays) and on a GCMS-
291QP2010 selective detector connected to a GC-2010 gas
292chromatograph from Shimadzu (Ct MEF and TKO MEF
293assays). The settingswere as follows:GC inlet 230C (200C
294for lactate measurement), transfer line 280C, MS source
295230CandMSQuad 150C.AnHP-5 or aDB-5MS capillary
296column (both: length (m), 30; internal diameter (lm), 250;
297film thickness (lm), 0.25) was used. Spectral data were
298corrected using regression analysis to extract natural
13C
299enrichment from results (Lee et al. 1991). Measurement of
300
13C label distribution determined the different relative dis-
301tribution percentages of the isotopologues, m0 (without any
302
13C labels),m1 (with one 13C),m2 (with two 13C), etc.,which
303were reported as molar fractions.
P
m is the sum of the
304labeled species (
P
m = m1 ? m2 ? m3…) and is repre-
305sentative of the synthesized molecules of each metabolite.
306The total label enrichment
P
mn is the weighted sum of the
307labeled species (
P
mn = m1 9 1?m2 9 2?m3 9 3…)
308and is representative of the contribution of the tracer used in
309the synthesis of each metabolite.
310Lactate from the cell culture medium was extracted with
311ethyl acetate after acidification with HCl. Lactate was
312transformed to its propylamide-heptafluorobutyric form
313and the ion cluster around m/z 328 (carbons 1–3 of lactate,
314chemical ionization) was monitored for the detection of m1
315(recycled lactate through the pentose cycle) and m2 (lactate
316produced by glycolysis). The relative amount of glucose
317that is converted indirectly to lactate through the pentose
318cycle, known here as pentose cycle activity, is calculated
319by the (m1/m2)/(3 ? (m1/m2)) ratio using lactate isoto-
320pologues (Lee et al. 1998).
321RNA ribose was isolated by acid hydrolysis of cellular
322RNA after Trizol-purification of cell extracts. Ribose iso-
323lated from RNA was transformed to its aldonitrile-acetate
324form using hydroxylamine in pyridine and acetic anhy-
325dride. We monitored the ion cluster around the m/z 256
326(carbons 1–5 of ribose, chemical ionization) to find the
327molar enrichment and positional distribution of
13C labels
328in ribose (Boros et al. 1997; Lee et al. 1998). The m2 ribose
329originated from [1,2-
13C2]-glucose that is converted to
330ribose through transketolase enzyme reactions, whereas m1
M. Zanuy et al.
123
Journal : Large 11306 Dispatch : 27-6-2011 Pages : 11
Article No. : 328
h LE h TYPESET
MS Code : MEBO-474 h CP h DISK4 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
331 ribose originated from glucose metabolized by direct oxi-
332 dation via the oxidative steps of the PPP. The isotopo-
333 logues m3 and m4 come from the recycling of the
334 previously labeled riboses. The oxidative versus non-oxi-
335 dative ratio was measured as ox/non-ox = (m1 ? m3)/
336 (m2 ? m3 ? 29m4).
337 2.9 Sugars-phosphate determination
338 Hexose, triose, pentose and fructose-1,6-bis-phosphates were
339 determined in cell monolayers frozen in liquid nitrogen as
340 described (Vizan et al. 2007). Frozen cells were briefly
341 scraped off the plates and 100 mM acetic acid solution at 4C
342 was added. The obtained homogenates were centrifuged at
343 0.49g for 10 min at 4C, and the supernatants containing
344 sugar phosphate molecules were separated and kept frozen at
345 -80C for the following liquid chromatography/mass spec-
346 trometry (LC–MS) analysis. Chromatographywas performed
347 using an Agilent 1100 Quaternary Pump (Agilent Technolo-
348 gies) equipped with a refrigerated autosampler. A Nucleodex
349 b-OH high-performance liquid chromatography (HPLC)
350 column, 200 9 4 mm i.d. (Panreac Quı´mica S.A.U.) with a
351 binary gradient at a flow-rate of 0.75 ml/min was used. Sol-
352 vent A consisted of 10 mM ammonium acetate pH 4.0. Sol-
353 vent B consisted of acetonitrile. Before reaching the mass
354 spectrometer, the flow-rate was split (1:3). To reduce the
355 residualmatrix effect reaching themass spectrometer, a divert
356 valve (VICI Valco Instruments) drained off the LC eluent
357 during the time in which interference was detected in order to
358 avoid contamination of the mass spectrometer. Identification
359 of sugar phosphates was carried out in an API-3000 tandem
360 mass spectrometer (Applied Biosystems). The multiple reac-
361 tion monitoring (MRM) transitions were 259/97 for glucose-
362 6-phosphate and fructose-6-phosphate (hexose phosphates),
363 199/97 for glyceraldehyde-3-phosphate and dihydroxyace-
364 tone phosphate (triose phosphates), 339/97 for fructose-1,6-
365 bisphosphate and229/97 for ribose-5-phosphate andxylulose-
366 5-phosphate (pentose phosphates).
367 2.10 Data analysis and statistical methods
368 In vitro experiments were carried out using three cultures
369 each time for each treatment regimen and then repeated
370 twice. Mass spectral analyses were carried out by three
371 independent automatic injections of 1 ll of each sample by
372 means of the automatic sampler and accepted only if the
373 sample standard deviation was less than 1% of the nor-
374 malized peak intensity. Statistical analyses were performed
375 using the parametric unpaired, two-tailed independent
376 sample t test with 95, 99, and 99.9% confidence intervals,
377 and P\ 0.05, P\ 0.01, and P\ 0.001 were considered,
378 respectively, to indicate significant differences in glucose
379 carbon metabolism.
3803 Results
3813.1 Selection of a better CDK4 and CDK6 inhibitor
382Results from CDK6-p16
INK4a complex dynamics were used
383to model the interaction pattern of the putative inhibitors.
384The ACD 3D database (available chemical database 3D)
385was screened for commercial compounds that matched our
386query. After docking procedures, eight compounds were
387selected for further experimental kinase assays, with cal-
388cein being the most active (Figure SM1, Supplementary
389Material).
3903.2 Calcein selectively inhibits CDK4 and CDK6
391activities, disrupting cell growth, pRb and cell
392cycle
393To investigate whether calcein selectively inhibits CDK4
394and CDK6 activities, immunoprecipitations were per-
395formed, followed by kinase assays in the presence or absence
396of calcein. A dose–response curve with increasing doses of
397calcein from 10 lM to 500 lM was carried out with
398immunoprecipitatedCDK6 (Fig. 1a),with an IC50 of 75 lM.
399Calcein at this concentration produced similar effects when
400CDK4, cyclin D1 or cyclin D3 were immunoprecipitated
401(Fig. 1b), but did not inhibit CDK1 or CDK2 kinase activi-
402ties at any of the concentrations tested (Figure SM2.A sup-
403plementary material). As expected from in silico complex
404dynamics, the interaction of calceinwithCDK6 seemed to be
405through the p16
INK4a binding site, as calcein was able to
406displace p16
INK4a from the immunoprecipitated enzyme
407(Figure SM2.B, supplementary material). These results
408demonstrate that calcein interacts selectively with CDK4
409and CDK6 at the p16
INK4a binding site, inhibiting their
410kinase activitywithout affectingCDK2andCDK1 activities.
411To examine whether calcein penetrates the cell mem-
412brane and inhibits intracellular CDK4 and CDK6 activities,
413we used human colon adenocarcinoma HCT116 cells, as
414they have a silenced wild-type p16
INK4A gene and only
415express a mutant allele (Myohanen et al. 1998). Increasing
416doses of calcein in the media induced a progressive inhi-
417bition of HCT116 cell viability, presenting a rather high
418IC50 of 400 lM after 72 h of treatment. The calcein acet-
419oxymethyl-ester (calcein AM) and tert-butoxy methyl ester
420(calcein tBM), which are more lipophilic and diffusible
421through the cytoplasmic membrane than the non-esterified
422calcein, induced a stronger inhibition of HCT116 cell
423viability, with IC50 values of 0.6 and 80 lM, respectively.
424Treatment of HCT116 cells with the non-esterified calcein
425or with calcein AM decreased the phosphorylation of the
426serine 780 of pRb, which is a specific target for CDK4 and
427CDK6 (Fig. 2a). In addition, calcein AM arrested the cell
428cycle in G1 of synchronous HCT116 cells (Fig. 2b).
CDK inhibition perturbs pentose phosphate pathway and cell viability
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429 All these data suggest a molecular mechanism of action
430 of calcein and its esters through the inhibition of CDK4 and
431 CDK6, which in turn affects cell cycle regulation.
432 3.3 Metabolic effects caused by the inhibition
433 of the CDKs responsible for G1/S transition
434 HCT116 human colon adenocarcinoma cells exposed to
435 increasing concentrations of calcein AM were incubated
436 for 72 h with 10 mM glucose 50% enriched in [1,2-
13C2]-
437 D-glucose. The calcein AM concentrations were the IC25
438 (0.36 lM), IC50 (0.61 lM) and IC75 (1.0 lM) after 72 h of
439 treatment. In parallel, we also performed incubations with
440 immortalized mouse embryonic fibroblasts (Ct MEF)
441 control and knockout for CDK4, CDK6 and CDK2 (TKO
442 MEF) in the presence of the same tracer, to check whether
443 the metabolic changes induced by calcein AM on HCT116
444 cells were characteristic of the inhibition of the CDKs
445 responsible for the G1/S transition. These MEF cell lines
446 (Ct and TKO) constitute an additional new tool that could
447elucidate the effects of the permanent absence of these
448CDKs in vivo and their contributions to cell cycle pro-
449gression and the robust tumor metabolic adaptation.
450Lactate and ribose from RNA synthesized from the
451tracer [1,2-
13C2]-D-glucose were measured using gas
452chromatography coupled to mass spectrometry (GC–MS).
453Table 1 shows the pondered values of the
13C-enriched
454isotopologues, m1/Rm and m2/Rm, of lactate and ribose
455from RNA. The molar enrichment Rmn of ribose from
456RNA is also shown.
457Lactate m2 isotopologues (lactate molecules that con-
458tain two
13C atoms) originated from [1,2-13C2]-D-glucose
459converted to lactate through glycolysis, whereas lactate m1
460isotopologues originated from the metabolization of the
461tracer through the oxidative step of the PPP and then
462recycled to glycolysis via the non-oxidative PPP. Calcein
463AM induced a dose–response decrease of m1/Rm and an
464increase of m2/Rm in HCT116 cells. This drop of m1/Rm
465suggests that calcein AM reduces the contribution of the
466oxidative PPP flux in lactate synthesis. Similarly, when
Fig. 1 Effect of calcein on
kinase assays in
inmunoprecipitated CDK6,
CDK4, cyclin D1, and cyclin
D3. a Dose–effect curve of non-
esterified calcein on CDK6
activity (10–500 lM). b CDK4,
cyclin D1 and cyclin D3
immunoprecipitations and
kinase assays tested in the
presence of 75 lM of non-
esterified calcein and p16INK4a
(3 lM). pGST-Rb (379–928)
fusion protein was used as a
substrate. Mean ? SD; n = 3.
(*) indicates P\ 0.05 and (**)
indicates P\ 0.01 compared to
vehicle
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467 MEF cell lines were incubated with [1,2-
13C2]-D-glucose,
468 the deletion of CDK4, CDK6 and CDK2 reduced m1/Rm
469 lactate, indicating that TKO MEF cells had a reduced
470 contribution of the oxidative pathway of PPP in lactate
471 synthesis. Moreover, the pentose cycle activity decreased
472 progressively in HCT116 cells treated with growing doses
473of calcein AM, and was 13.75% lower in the condition
474where the cells were treated with the calcein AM IC75
475concentration (0.026 ± 0.001 in Ct vs. 0.023 ± 0.001 in
476IC75). Similarly, pentose cycle activity in TKO MEF cells
477was 32.35% lower than in Ct MEF (0.040 ± 0.002 in Ct
478vs. 0.027 ± 0.008 in TKO). This decreased pentose cycle
Fig. 2 Phosphorylation of
serine780 of pRb and cell cycle
analysis. a HCT116 cells were
treated with 400 lM or with 0.6
and 2 lM of calcein AM for
24 h and the extracts were
blotted specifically against
phosphoserine 780 of pRb.
b Synchronous HCT116 cells in
the G1 phase at time 0 h (t0
synchronous control) and after
24 h with or without treatment
with calcein AM 2 lM. (*)
indicates P\ 0.05 and (**)
indicates P\ 0.01. Both
experiments were performed
three times (Mean ? SD;
n = 3). One representative
example is shown in each case
Table 1 Isotopologue distribution in lactate and ribose. M1/Rm and m2/Rm were determined in lactate isolated from incubation medium and
in ribose isolated from RNA. Rmn in ribose isolated from RNA was also measured
Isotopologue distribution analysis
HCT116 MEF
Lactate Ct IC25 IC50 IC75 Ct TKO
m1/
P
m 0.075 ± 0.003 0.075 ± 0.001 0.064 ± 0.003** 0.065 ± 0.002** 0.104 ± 0.000 0.070 ± 0.020*
m2/
P
m 0.919 ± 0.003 0.918 ± 0.002 0.928 ± 0.002** 0.926 ± 0.002* 0.835 ± 0.049 0.843 ± 0.043
Ribose Ct IC25 IC50 IC75 Ct TKO
m1/
P
m 0.544 ± 0.003 0.522 ± 0.002*** 0.496 ± 0.003*** 0.474 ± 0.003*** 0.450 ± 0.002 0.414 ± 0.002***
m2/
P
m 0.303 ± 0.000 0.324 ± 0.001*** 0.343 ± 0.004*** 0.364 ± 0.002*** 0.385 ± 0.002 0.420 ± 0.002***
P
mn 0.839 ± 0.016 0.858 ± 0.030 0.811 ± 0.098** 0.668 ± 0.055* 0.754 ± 0.008 0.718 ± 0.008**
* P\ 0.05; ** P\ 0.01; *** P\ 0.001. Experiments were performed twice. Results from one of them are shown (Mean ? SD; n = 3)
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479 activity reinforced the hypothesis of a diminution of the
480 oxidative PPP flux and a decrease in its contribution to
481 glucose metabolism when the G1/S-phase of the cell cycle
482 is perturbed.
483 Calcein AM treatment in HCT116 cells also resulted in
484 a slight decrease in the incorporation of
13C atoms from
485 glucose into nucleic acid ribose (Table 1). The average
486 number of
13C atoms per ribose molecule (Rmn) was
487 reduced by 20% at the dose of IC75 of calcein AM in
488 HCT116 cells. As suggested by the above-described
489 decrease in lactate m1/Rm data, the reduction of ribose
490 synthesis in HCT116 cells could be caused by reduced
491 substrate flux through the oxidative steps of the PPP.
492 Furthermore, calcein AM treatment in HCT116 cells
493 caused a dose-dependent m1/Rm decrease as well as a
494 linear increase of m2/Rm ribose (Table 1). This was in
495 accordance with the results obtained in lactate measure-
496 ments and denoted a clear attenuation of the flux through
497 the oxidative PPP.
498 Furthermore, TKO MEFs had a lower proliferation rate
499 than Ct MEFs (Ct MEF: 0.26 h
-1 vs. TKO MEF:
500 0.12 h
-1), the total label incorporation in ribose (Rmn)
501 being lower than that of Ct MEFs (Table 1). Moreover,
502 deletion of CDK4, CDK6 and CDK2 resulted in a decrease
503 in the percentage of ribose m1/Rm and an increase in
504 ribose m2/Rm, which suggests a decrease in the use of the
505 oxidative branch of the PPP. This was in accordance with
506 the results obtained in lactate measurements and denoted a
507 clear attenuation of the flux through the oxidative PPP.
508 Similarly, the oxidative/non-oxidative ratio of PPP was
509 14% lower for TKO MEFs than for Ct MEFs (0.78 ± 0.00
510 and 0.91 ± 0.01, respectively). Equally, all calcein AM
511 treatments showed a lower oxidative/non-oxidative ratio of
512 PPP compared to the control treatments (8.42, 18, and
513 31.90% lower for the IC25, IC50, and IC75 treated HCT116,
514 respectively, 1.27 ± 0.00 being for control HCT116 cells).
515 It has been reported that this ratio is higher in tumor cells
516 compared to normal cells (Ramos-Montoya et al. 2006).
517 To provide information on the relative importance of the
518 two pathways of pentose phosphate production for the
519 viability of the cell, we used phenotype phase-plane anal-
520 ysis. Phenotype phase-plane analysis is the analysis of
521 substrate production and utilization of cells and is an
522 important aspect of reaction network analysis (Edwards
523 et al. 2002; Lee 2006). Figure 3 contains the phase-plane
524 analysis of the normalized ribose isotopologues m1 and
525 m2, where values for oxidative ribose synthesis are plotted
526 against non-oxidative ribose synthesis. The line of opti-
527 mality is arbitrarily defined as the line drawn through the
528 point for the basal state (Ct Control treatment or Ct MEF)
529 corresponding to conditions satisfying the optimal condi-
530 tions for growth (objective function). The slope of the line
531 represents the optimal ratio of ribose formed through the
532oxidative pentose phosphate pathway to a given level of
533non-oxidative ribose synthesis for the tumor cells. When a
534line is drawn from a phenotype (a point on the phase-
535plane), parallel to the major axis, the intersection between
536the line of optimality and the parallel line indicates the
537degree of optimality relative to the basal state. Using
538metabolic phenotype phase-plane analysis, we saw that
539increasing doses of calcein AM or the deletion of the main
540CDKs of the G1/S-phase transition resulted in a more
541dramatic imbalance between oxidative/non-oxidative PPP.
542According to these data, the representation of m1/Rm vs
543m2/Rm in a phenotype phase-plane analysis confirmed the
544same tendency as in calcein AM-treated cells: the deletion
545of the CDKs, which phosphorylate pRb, caused an imbal-
546ance of the PPP towards the non-oxidative branch (Fig. 3).
5473.4 Sugar phosphate pool decreases when cell cycle
548does not progress
549Changes in the absolute concentrations of the intermediary
550sugar phosphates reflect variations in the metabolic flux
551profile distribution. Pentose phosphate, triose phosphate
552and hexose phosphate pools were quantified in HCT116
553cells treated with IC50 of calcein AM (0.6 lM) and control
Fig. 3 13C ribose label distribution. Phase-plane analysis of the
normalized ribose isotopologues m1 and m2. a HCT116 cells treated
without (Ct) or with IC25, IC50, and IC75 doses of calcein AM; and
b the control mouse embryonic fibroblasts (Ct MEF) and the MEF
knockout for CDK4, CDK6, and CDK2 (TKO MEF)
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554 and TKO MEFs (data not shown). Inhibition of CDK4 and
555 CDK6 function using a calcein AM inhibitor or the
556 knockout cell model resulted in decrease in the concen-
557 tration of fructose-1,6-bisphosphate, pentose and triose
558 phosphate intermediaries. Although, these changes were
559 not significant, they showed a tendency in which the arrest
560 in the G1 phase of the cell cycle alters the profile of sugar
561 phosphate concentrations.
562 4 Discussion
563 Evidence indicates that CDK4 and CDK6 are excellent
564 targets for the design of new anti-tumor drugs (Landis et al.
565 2006; Yu et al. 2006; Malumbres and Barbacid 2006;
566 Marzec et al. 2006). However, the design of good specific
567 inhibitors against the activity of these kinases has not been
568 successful until now. Different strategies have been
569 employed in the search for good inhibitors but almost none
570 of them have been successful due to their unspecificity and
571 the subsequent side effects (Fry et al. 2004; McInnes 2008;
572 Menu et al. 2008). Thus, there is emerging interest in
573 developing new strategies to search for selective inhibitors
574 of CDK4 and CDK6 for cancer chemotherapy (Mahale
575 et al. 2006). To this end, in this study we used a new set of
576 bioinformatic tools to design CDK4 and CDK6 inhibitors
577 that mimic their natural inhibitor p16
INK4a. One of these
578 inhibitors was calcein.
579 Calcein AM is a fluorescent dye that localizes intracel-
580 lularly after esterase-dependent cellular trapping and has
581 shown cytotoxic activity against various established human
582 tumor cell lines at relatively low concentrations (Jonsson
583 et al. 1996; Liminga et al. 2000). Furthermore, Liminga
584 and collaborators found that calcein AM caused a strong
585 apoptotic response within hours of exposure and tested it
586 on a panel of ten different cell lines, but they failed to find
587 its precise mechanism of action to inhibit cell proliferation
588 (Liminga et al. 1999; Liminga et al. 2000; Liminga et al.
589 1995). According to our results, calcein carboxylic esters
590 easily penetrate HCT116 cells, inhibiting cell viability at
591 relatively low doses compared with the non-esterified cal-
592 cein. We have also shown that calcein (the active form
593 inside the cell of the calcein AM ester) specifically inhib-
594 ited CDK4 and CDK6 (cyclin D-related activities),
595 inducing inhibition of pRb phosphorylation, which is
596 required for entering the S-phase of the cell cycle (Lund-
597 berg and Weinberg 1998; Malumbres et al. 2004). The
598 potential of calcein to avoid the entrance of treated cells
599 into the S-phase was further validated here, as calcein AM
600 treatment on HCT116 cells provoked a strong G1-phase
601 cell cycle arrest.
602 Having elucidated the effects of calcein on the cell cycle,
603 we proceeded to characterize in depth the effects of
604inhibiting CDK4 and CDK6 activities on the metabolic
605profile of the HCT116 cells. We have previously demon-
606strated that the balance between oxidative and non-oxidative
607branches of the PPP is essential to maintain proliferation in
608cancer cells and is a vulnerable target within the cancer
609metabolic network for potential new therapies for over-
610coming drug resistance (Ramos-Montoya et al. 2006). Our
611results here show that increasingly high calcein AM con-
612centrations result in a stronger imbalance of PPP in favor of
613the non-oxidative branch (Fig. 4). Using metabolic pheno-
614type phase-plane analysis, we deduced that themost efficient
615doses of calcein AM in the inhibition of tumor cell growth
616result in a more dramatic imbalance between oxidative and
617non-oxidative branches of PPP. The perturbation of this
618imbalance results in a state of metabolic inefficiency and
619consequently could lead to a pause in cell proliferation or
620even cell apoptosis. To ensure that the metabolic alterations
621induced by calcein AM in HCT116 cells were due to the
622specific inhibition of CDK4 and CDK6 activities induced by
623this compound, we also characterized the metabolic profile
624of control (Ct) and triple knockout (TKO) MEFs. These
625results showed that the lack of functionality of CDK4, CDK6
626and CDK2 induced changes in the metabolic profile of
627fibroblasts that correlate with the alterations induced by
628calcein AM in the metabolic profile of HCT116 tumor cells.
629These results support our hypothesis that inhibition of CDK4
630and CDK6 was responsible for the oxidative/non-oxidative
631imbalance in PPP induced by calcein AM.
632We recently reported a specific increase in the activities of
633two key enzymes of PPP, glucose-6-phosphate dehydroge-
634nase for the oxidative branch and transketolase for the non-
635oxidative branch, during the S/G2 phases of the cell cycle, in
636particular during the S-phase, when the synthesis of nucle-
637otides is required. Such an increase in the PPP enzyme
Fig. 4 Metabolic changes associated to CDK4/6 inhibition. CDK4
and CDK6 inhibition leads to an imbalance between the oxidative and
non-oxidative branches of the pentose phosphate pathway towards the
non-oxidative branch. Thick lines indicate enhanced metabolic routes.
Dotted lines indicate less active metabolic routes and smaller font
sizes indicate lower intermediate concentrations
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638 activities correlates with a relative increase in the pentose
639 phosphate pool and a progressive increase in the balance
640 between oxidative and non-oxidative branches of PPP in the
641 S and G2 phases (Vizan et al. 2009). This means that the
642 contribution of the oxidative branch to ribose-5-phosphate
643 synthesis is relatively increased when the cycle progresses
644 through the S-phase (Vizan et al. 2009). In this article, the
645 results support this assertion, showing a decrease in this
646 balance whenHCT116 cells were treatedwith calceinAMor
647 when fibroblasts did not express functional CDK4, CDK6,
648 and CDK2 and their progress through the cell cycle was
649 compromised. Moreover,
13C incorporation from glucose
650 into RNA ribose was lower both in HCT116 treated with
651 calcein AM and in TKO MEFs, indicating that ribose-5-
652 phosphate synthesis decreases when the entrance of the cell
653 into the S-phase is inhibited. Additionally, in this work we
654 have shown that the imbalance in PPP induced by the inhi-
655 bition of CDK4 andCDK6 is able to slightly compromise the
656 balance in the overall central carbon metabolic network of
657 the cell, which is reflected in a non-significant change in the
658 levels of intermediary sugar phosphates (Fig. 4). The results
659 presented in this paper regarding the metabolic conse-
660 quences of the inhibition of CDK4 and CDK6 highlights the
661 metabolic requirements of the cell cycle and points to CDK4
662 and CDK6 as interesting drug targets to be explored in a
663 wider range of cancer types.
664 5 Concluding remarks
665 The forced imbalance of the PPP towards the oxidative
666 branch is a possible Achilles’ heel in the robust tumor
667 metabolic adaptation. It has been shown that effective anti-
668 tumor strategies against this target can be designed not only
669 with drugs that force this imbalance even further (Ramos-
670 Montoya et al. 2006), but also using drugs that recover the
671 oxidative/non-oxidative balance in the non-tumor cells.
672 The data presented here demonstrate that the inhibition of
673 CDK4 and CDK6 using calcein AM not only inhibits the
674 progression of the cell cycle, but also disrupts this oxida-
675 tive/non-oxidative imbalance of PPP, which has been
676 described as essential for tumor proliferation, reinforcing
677 the interest of CDK4 and CDK6 as targets in cancer
678 therapy.
679 Furthermore, we suggest that calcein could be a key
680 factor in the development of a new family of selective
681 cyclin D-dependent kinases inhibitors based on its struc-
682 ture. The improved understanding of the specific effects of
683 the inhibition of CDK4 and CDK6 on tumor cell central
684 metabolic networks shown in this paper opens up new
685 avenues for the design of combination therapies with drugs
686 that directly inhibit those pathways and also to the use of
687specific CDK4 and CDK6 inhibitors to impair metabolic
688adaptations that support tumor cell cycle progression.
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